Long-Term Safety and Efficacy Study of Peginterferon Beta-1a
Completed · Phase 3
Conditions studied: Relapsing Multiple Sclerosis
In brief
The primary objective of this study is to evaluate the long-term safety and tolerability of peginterferon beta-1a (BIIB017) in participants originally treated in Study 105MS301 (NCT00906399) who continue peginterferon beta-1a treatment. The secondary objective of this study is to describe long-term multiple sclerosis (MS) outcomes in participants originally treated in Study 105MS301 (NCT00906399) who continue peginterferon beta-1a treatment.
Key facts
- Study ID
- NCT01332019
- Run by
- Biogen
- People needed
- 1077
- Starts
- 2011-04-01
- Expected to finish
- 2015-10-01
- Last updated by the study team
- 2017-01-13
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Research Site — Lexington, Kentucky, United States
- Research Site — Baltimore, Maryland, United States
- Research Site — Raleigh, North Carolina, United States
- Research Site — Akron, Ohio, United States
- Research Site — Cleveland, Ohio, United States
- Research Site — Franklin, Tennessee, United States
- Research Site — Sint-Truiden, Belgium
- Research Site — Plovdiv, Bulgaria
- Research Site — Sofia, Bulgaria
- Research Site — Sofia, Bulgaria
- Research Site — Sofia, Bulgaria
- Research Site — Sofia, Bulgaria
- Research Site — Sofia, Bulgaria
- Research Site — London, Ontario, Canada
- Research Site — Montreal, Quebec, Canada
- Research Site — Santiago, Chile
- Research Site — Barranquilla, Colombia
- Research Site — Bogotá, Colombia
- Research Site — Zagreb, Croatia
- Research Site — Brno, Czechia
- Research Site — Havffov, Czechia
- Research Site — Olomouc, Czechia
- Research Site — Ostrava, Czechia
- Research Site — Ostrava-Vitkovice, Czechia
- Research Site — Atlanta, Georgia, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.